T Cell News and Research

Latest T Cell News and Research

Researchers develop new application for improved detection of breast cancer cells

Single-walled nanotubes—cylinders of carbon about a nanometer in diameter—have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for fuel cells. Thanks to a new development by researchers at the National Institute of Standards and Technology (NIST) and five partners, you can add one more application to the list: detection and destruction of an aggressive form of breast cancer.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival, according to research from The University of Texas M. D. Anderson Cancer Center.

2 Dec 2009

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the results of a study demonstrating for the first time the capability to detect and automatically measure key activity indicators of cancer cell signal transduction pathways in intact tissue.

2 Dec 2009

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana.

2 Dec 2009

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Cancer researchers at the University of Oklahoma Health Sciences Center have found a way to turn ineffective new cancer drugs into cancer-fighters. By using their patented chemical compound, SHetA2, researchers tricked cancer cells into responding to new treatments and undergoing cell suicide.

2 Dec 2009

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

Cell Therapeutics, Inc. (CTI) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

2 Dec 2009

TGF--1 suppresses the growth of cancer cells, find researchers

UT Southwestern Medical Center researchers have found that a naturally occurring protein -- transforming growth factor beta1 (TGF--1) -- which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.

2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Research study on the function of orexin neurons in brain

Japanese research group led by Professor Yasuhiko Minokoshi and Dr. Tetsuya Shiuchi, scientists at the National Institute for Physiological Sciences, NIPS, Japan, found that meals stimulated with sweet taste and motivated with its anticipation regularly activates "orexin" in the brain and it stimulates muscle glucose metabolism via the sympathetic nervous system, thereby reducing blood glucose level in mice.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

ASH to host annual High School Student Symposium at New Orleans Marriott

The American Society of Hematology (ASH) will host its annual High School Student Symposium at the New Orleans Marriott on Thursday, December 3, at 8:00 a.m. CST.

1 Dec 2009

Stem Cell Therapy International and Histostem sign distribution agreement

Stem Cell Therapy International Inc. (OTCBB: SCII) announced that it has signed an agreement with Histostem Ltd. of South Korea ("Histostem"), for the exclusive, worldwide rights to the distribution of the Company's existing SteMixx line of stem cell based cosmetic products, as well as future products under development. Previously available for purchase only in Korea, SteMixx received approval last month from the Korean FDA as an effective cosmetic for the treatment of aging skin.

1 Dec 2009

Sperm genes may have a detrimental effect on longevity, says new study

Researchers in Japan have found that female mice produced by using genetic material from two mothers but no father live significantly longer than mice with the normal mix of maternal and paternal genes. Their findings provide the first evidence that sperm genes may have a detrimental effect on lifespan in mammals.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

Pfizer and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease.

1 Dec 2009

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

StemCyte, Inc. concluded an exclusive license and commercialization agreement with Academia Sinica, the National Laboratory of Taiwan, for certain proprietary methods and Intellectual Property (IP) related to the treatment of Chronic Stroke with stem cells.

1 Dec 2009

TAP and pharma company team up to design Sonata, a unique system to speed drug development

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is delighted to announce that its Advanced Projects Group has partnered with a leading pharma company to successfully design and deliver Sonata™, a unique system for automated culturing and processing of cell lines in shake flasks.

1 Dec 2009

Glutamatergic nerve cells regularly generated in the brain

Until only a few years ago, neurogenesis - the process of nerve cell development - was considered to be impossible in the adult brain. The textbooks asserted that dead nerve cells could not be replaced. Then researchers discovered regions in the forebrain in humans in which new nerve cells can be generated throughout life. These so-called GABAergic cells use gamma-aminobutyric acid (GABA), a neurotransmitter of the central nervous system.

1 Dec 2009

AHF lauds WHO for its crucial HIV treatment recommendations

On the eve of World AIDS Day 2009, AIDS Healthcare Foundation (AHF) praised the World Health Organization (WHO) for its new HIV treatment recommendations which include starting lifesaving antiretroviral treatment (ART) earlier (at a t-cell count of <350 cells/mm3 instead of <200) for all HIV-positive adults and adolescents and earlier treatment initiation for HIV-positive pregnant women who should now begin treatment at 14 weeks into pregnancy, rather than 28 weeks as previously recommended, and continue until the end of breastfeeding.

1 Dec 2009

T Cell News and Research

Latest T Cell News and Research

Researchers develop new application for improved detection of breast cancer cells

DiaMedica to acquire all issued and outstanding shares of Sanomune

CT imaging combined with Avastin may predict overall survival in metastatic colorectal cancer

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

New data on pixantrone Phase III trial in non-Hodgkin's lymphoma to be presented

TGF--1 suppresses the growth of cancer cells, find researchers

Canadians with hemophilia A can use new treatment option, XYNTHA

Research study on the function of orexin neurons in brain

CRO to run CEL-SCI's upcoming Phase III clinical trial

ASH to host annual High School Student Symposium at New Orleans Marriott

Stem Cell Therapy International and Histostem sign distribution agreement

Sperm genes may have a detrimental effect on longevity, says new study

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

TAP and pharma company team up to design Sonata, a unique system to speed drug development

Glutamatergic nerve cells regularly generated in the brain

AHF lauds WHO for its crucial HIV treatment recommendations

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in